HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) is a funding call from National Institutes of Health that closes 20 February 2029. Funding: Total program funding $11,000,000. Eligibility: NIH-style eligibility: US institutions only; non-US (foreign) organisations are not eligible to apply.
- Funder
- National Institutes of Health
- Deadline
- 20 Feb 2029 (859 days)
- Amount
- Total program funding $11,000,000
- Region / eligibility
- United States
- Career stage
- established / PI
- Fields
- chemistry, pharma process
- Reference
- RFA-NS-27-007
- Official call
- Grants.gov listing
Eligibility in plain language
NIH-style eligibility: US institutions only; non-US (foreign) organisations are not eligible to apply.
Who should apply
Synthetic, physical and analytical chemists, medicinal chemists and pharma process / drug-development teams — best fit for PIs and research groups.
Summary from source
The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing. This is a mileston…